On February 7, 2024, CVS Health Corporation reported its fourth quarter and full-year results for the period ending December 31, 2023. The company announced an 11.9% increase in total revenues for the quarter, reaching $93.8 billion, and a 10.9% increase for the full year, totaling $357.8 billion. GAAP diluted EPS was $1.58 for the quarter and $6.47 for the full year, while Adjusted EPS was $2.12 for the quarter and $8.74 for the full year. The company also generated $13.4 billion in cash flow from operations during the year. CVS Health revised its 2024 full-year guidance, lowering GAAP diluted EPS to at least $7.06 from $7.26, Adjusted EPS to at least $8.30 from $8.50, and cash flow from operations to at least $12.0 billion from $12.5 billion, due to elevated medical cost trends. CVS Health President and CEO...Show More

On February 7, 2024, CVS Health Corporation reported its fourth quarter and full-year results for the period ending December 31, 2023. The company announced an 11.9% increase in total revenues for the quarter, reaching $93.8 billion, and a 10.9% increase for the full year, totaling $357.8 billion. GAAP diluted EPS was $1.58 for the quarter and $6.47 for the full year, while Adjusted EPS was $2.12 for the quarter and $8.74 for the full year. The company also generated $13.4 billion in cash flow from operations during the year. CVS Health revised its 2024 full-year guidance, lowering GAAP diluted EPS to at least $7.06 from $7.26, Adjusted EPS to at least $8.30 from $8.50, and cash flow from operations to at least $12.0 billion from $12.5 billion, due to elevated medical cost trends. CVS Health President and CEO Karen S. Lynch highlighted the company's focus on delivering care and value, and the introduction of new models like CVS CostVantage and CVS Caremark TrueCost aimed at increasing transparency and affordability. The company also announced a 10% increase in the quarterly shareholder dividend effective February 1, 2024, and returned $3.1 billion to shareholders through dividends in 2023.